Drop the Nycomed, keep the Amersham, said shareholders at the May 9 company meeting. The change will take place “as soon as practicable,” according to
Drop the Nycomed, keep the Amersham, said shareholders at the May 9 company meeting. The change will take place “as soon as practicable,” according to Amersham.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.